ஜூலியா களஞ்சியங்கள் களை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஜூலியா களஞ்சியங்கள் களை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஜூலியா களஞ்சியங்கள் களை Today - Breaking & Trending Today

Developing countries sidelined in Covid-19 vaccine scramble

Lack of funds and local manufacturing capacity has prevented Covax from competing with wealthier nations’ self-interest ....

South Africa , United States , Toyin Abiodun , Bruce Aylward , Donald Trump , Lorin Levine , Ingrid Katz , Tedros Adhanom Ghebreyegsus , Julia Barnes Weise , Ngozi Okonjo Iweala , Atlantic Council , World Health Organization , Harvard Global Health Institute , Melinda Gates Foundation , World Bank , Vaccine Alliance , Coalition For Epidemic Preparedness , Tony Blair Institute For Global , Serum Institute Of India , World Trade Organisation , Gates Foundation , Epidemic Preparedness , World Health , Global Healthcare Innovation Alliances , Defense Production , Harvard Global Health ,

High-tech problem for Joe Biden's COVID vaccine patent waiver

Print this article
The difficulty of learning the technology behind mRNA vaccines poses a major obstacle to President Joe Biden s proposal aiding poor countries by defying the pharmaceutical industry and waiving patent protections for COVID-19 vaccines.
The rationale for the patent waiver would be to allow developing countries to reproduce currently existing COVID-19 vaccines without having to worry about getting sued by the pharmaceutical companies that hold the patents.
But in the case of the mRNA vaccines produced by Pfizer/BioNTech and Moderna, doing so would be very difficult. As of March, mRNA vaccines accounted for 43% of the COVID-19 vaccines produced, according to British software company Airfinity. ....

United Kingdom , United States , City Of , Julia Barnes Weise , Zoltan Kis , Joe Biden , Derek Lowe , Santos Rutschman , Vaccine Manufacturing Hub At Imperial College London , Saint Louis University School Of Law , Global Healthcare Innovation Alliance Accelerator , President Joe Biden , Future Vaccine Manufacturing Hub , Imperial College London , Ana Santos Rutschman , Saint Louis University School , Global Healthcare Innovation Alliance , ஒன்றுபட்டது கிஂக்டம் , ஒன்றுபட்டது மாநிலங்களில் , நகரம் ஆஃப் , ஜூலியா களஞ்சியங்கள் களை , ஸோல்டந் கீச் , ஓஹோ பிடென் , டெரெக் குறைந்த , தடுப்பூசி உற்பத்தி மையம் இல் ஏகாதிபத்தியம் கல்லூரி லண்டன் , துறவி லூயிஸ் பல்கலைக்கழகம் பள்ளி ஆஃப் சட்டம் ,

Biden's waiver of vaccine patents helps, but it's not enough

Print
The pharmaceutical industry, which thought it had entered the can-do-no-wrong stage of public esteem thanks to its development of COVID-19 vaccines in record time, just got taken down a peg by the Biden administration.
On Wednesday, the administration said it supports waiving patent protections for those same vaccines to help combat the pandemic around the world.
Drugmakers, which were counting on lavish profits from the vaccines, squealed like stuck pigs. Phrma, their leading trade group, called the policy “an unprecedented step that will undermine our global response to the pandemic and compromise safety.”
This is a global health crisis, and the extraordinary circumstances of the COVID-19 pandemic call for extraordinary measures. ....

South Africa , United States , Michael Hiltzik , Francis Collins , Anthony Fauci , William Moss , Santos Rutschman , Julia Barnes Weise , Katherine Tai , Dean Baker , National Institutes Of Health , York University , World Trade Organization , Defense Department , Biotechnology Innovation Organization , Representative Katherine Tai , Pulitzer Prize , International Vaccine Access Center , Johns Hopkins , South America , National Institutes , New York University , Ana Santos Rutschman , World Trade , Financial Times , Trade Representative Tai ,

Vaccine approvals offer hope as global Covid cases surge

By Anthony King, additional reporting by Bojan Stojkovski2021-01-14T16:35:00+00:00
As 2020 ended, news of the first Covid-19 vaccine approvals came as a huge relief to national governments and their citizens. Yet with Covid-19 infection rates rising in many countries, and with more infectious variants of the virus emerging, the need for widespread vaccination grows more urgent and regulators around the world are now racing to assess and approve vaccines.
The BioNTech-Pfizer vaccine was first approved by the UK on 2 December and now has approval in almost 50 countries. Moderna’s vaccine also gained emergency approval in the US and the UK in December, with the European Medicines Agency (EMA) greenlighting it last week. Both are RNA vaccines and have shown efficacies of around 95% in their clinical trials. ....

New York , United States , United Kingdom , United Arab Emirates , World Health Organization , Al Qahirah , John Moore , Dragan Danilovski , Julia Barnes Weise , Kim Mulholland , Peter Smith , Venko Filipce , Vaccine Alliance , Weill Cornell Medical College , Coalition For Epidemic Preparedness Innovations , European Union , Mcgill University , London School Of Hygiene Tropical Medicine , University Of Oxford , European Commission , Gamaleya Center , Kim Mulholland At Murdoch Children Research Institute , European Medicines Agency , Murdoch Children Research Institute , Murdoch Children , Research Institute ,

With First Dibs on Vaccines, Rich Countries Have 'Cleared the Shelves' But There's Some Good News for India

As a growing number of coronavirus vaccines advance through clinical trials, wealthy countries are fueling an extraordinary gap in access around the world, laying claim to more than half the doses that could come on the market by the end of next year.
While many poor nations may be able to vaccinate at most 20% of their populations in 2021, some of the world’s richest countries have reserved enough doses to immunize their own multiple times over.
With no guarantee that any particular vaccine would come through, these countries hedged their bets on a number of candidates. But if all the doses they have claimed are delivered, the European Union could inoculate its residents twice, Britain and the United States could do so four times over, and Canada six times over, according to a New York Times analysis of data on vaccine contracts collected by Duke University, UNICEF and Airfinity, a science analytics company. ....

New York , United States , United Kingdom , Saudi Arabia , United Arab Emirates , Bruce Aylward , Richard Hatchett , Donald Trump , Bill Gates , Andrea Taylor , Kendall Hoyt , Carlos Slim , Joe Biden , Julia Barnes Weise , Erin Otoole , Krishna Udayakumar , Adar Poonawalla , Clemens Auer , Canadian Parliament , University Of Oxford , World Health Organization , Global Healthcare Innovation Alliance Accelerator , Coalition For Epidemic Preparedness , New York Times , Duke Global Health Innovation Center , European Union ,